<DOC>
	<DOCNO>NCT01039350</DOCNO>
	<brief_summary>This open-label , single-arm , multicentre , prospective study darbepoetin alfa treat anaemia patient low intermediate-1 IPSS risk MDS . The study consist 14-day screening period follow maximum 24-week treatment period final visit .</brief_summary>
	<brief_title>Prospective , Multicenter , Open Label Single-arm Study Darbepoetin Alfa Anemia Myelodisplastic Syndrome Patients .</brief_title>
	<detailed_description>This open-label , single-arm , multicentre , prospective study darbepoetin alfa treat anaemia patient low intermediate-1 IPSS risk MDS . The study consist 14-day screening period follow maximum 24-week treatment period final visit . Darbepoetin alfa initiate dose 300 mcg QW SC period 8 week . After 8 week , erythroid response evaluate , treatment algorithm adapt . The study treatment period last maximum 24 week . The treatment end start week 24 . If schedule 24-week treatment period complete , end week last administration study drug . The follow-up period last minimum 4 week maximum 8 week last dose darbepoetin alfa . Subjects stratify enrolment accord IPSS ( low risk versus intermediate-1 risk ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Age ³ 18 year Low intermediate1 risk MDS accord IPSS , FAB classification RA , RARS , RAEB blast £ 10 % Predictive variable good response ( serum erythropoietin level &lt; 500 IU/l transfusion requirement &lt; 2 packed RBC/month precede 2 month ) Anaemia ( Hb £ 10 g/dL ) , confirm 14 day day 1 study Life expectancy least 6 month ECOG Performance status score 0 , 1 , 2 Subject must sign date Informed Consent ( approve Clinical Research Ethics Committee CREC ) , studyspecific procedure perform Known history convulsive disorder Poorly control hypertension ( diastolic blood pressure &gt; 100 mmHg ) screen Inadequate liver function ( total bilirubin &gt; two time upper limit normal range ( ULN ) , liver enzymes ( ALT , AST ) &gt; two time ULN ) Inadequate renal function ( serum creatinine concentration &gt; 2 mg/dL ) Ferritin &lt; 100 ng/ml transferrin saturation index ( TSI ) &lt; 16 % ; Vitamin B12 deficiency ( &lt; 200 pg/ml ) folate deficiency ( &lt; 2 ng/ml ) Clinicallyrelevant haemorrhages Haemolytic anaemia Cardiac condition : uncontrolled angina , congestive heart failure , uncontrolled cardiac arrhythmia Clinically significant systemic infection chronic inflammatory disease present time screen Any concomitant therapy use treat MDS ( include growth factor describe part protocol , chemotherapy , antibodybased cancer treatment , hormonal therapy , interferon , interleukin ) Treatment rHuEPO darbepoetin alfa 4 week prior Day 1 study More 2 RBC transfusion 28 day prior Day 1 study Pregnant breast feed woman Subjects childbearingpotential take adequate contraceptive measure , opinion investigator Known hypersensitivity mammalderived recombinant product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
</DOC>